Core Viewpoint - The company has announced the implementation of H-share full circulation, converting approximately 100.2 million unlisted shares held by 10 shareholders into H-shares, which represents about 59.7983% of the total issued shares as of the announcement date [1] Group 1 - The board of directors approved the proposal for H-share full circulation on November 26, 2025 [1] - The conversion involves shares held by 10 shareholders, totaling approximately 100.2 million shares [1] - The H-share full circulation will significantly increase the liquidity of the company's shares in the market [1]

Core Viewpoint - The company has announced the implementation of H-share full circulation, converting 100 million unlisted shares held by 10 shareholders into H-shares, which represents approximately 59.7983% of the total issued shares as of the announcement date [1] Group 1 - The board of directors approved the proposal for H-share full circulation on November 26, 2025 [1] - The conversion of unlisted shares into H-shares is subject to obtaining all necessary approvals, including filing with the China Securities Regulatory Commission [1] - The company will apply for the listing and trading of these H-shares on the main board of the Stock Exchange of Hong Kong [1] Group 2 - The conversion and listing do not require shareholder approval according to the company's articles of association [1]

Core Viewpoint - The company Wangshan Wangshui-B (02630) announced the implementation of a proposal for full circulation of H-shares, converting 100 million unlisted shares held by 10 shareholders into H-shares, which represents approximately 59.7983% of the total issued shares as of the announcement date [1] Group 1 - The board of directors approved the proposal for full circulation of H-shares on November 26, 2025 [1] - The conversion of the 100 million unlisted shares into H-shares is subject to obtaining all relevant approvals, including filing with the China Securities Regulatory Commission [1] - The company will apply to the Stock Exchange for approval for the listing and trading of the converted H-shares on the main board [1] Group 2 - According to the company's articles of association, the conversion and listing do not require approval from the shareholders' meeting [1]

（股份代號：2630） 內幕消息 本公司建議實施H股全流通 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 Vigonvita Life Sciences Co., Ltd. 蘇州旺山旺水生物醫藥股份有限公司 （於中華人民共和國註冊成立的股份有限公司） 承董事會命 蘇州旺山旺水生物醫藥股份有限公司 董事長、執行董事、首席執行官兼總經理 本公告乃由蘇州旺山旺水生物醫藥股份有限公司（「本公司」）根據香港聯合交易所 有限公司（「聯交所」）證券上市規則（「上市規則」）第13.09(2)條以及證券及期貨條 例（香港法例第571章）第XIVA部之內幕消息條文（定義見上市規則）而作出。 茲提述中國證券監督管理委員會（「中國證監會」）於2019年11月14日發佈並於 2023年8月10日進一步修訂的《H股公司境內未上市股份申請「全流通」業務指引》 （「指引」），內容有關H股於聯交所上市的公司申請非上市內資股（定義見指引）在 聯交所流通的程序。 根據指引，本公司董事（ ...

Core Viewpoint - ST Huaxi (002630.SZ) currently has no plans for share buybacks, indicating a focus on executing existing orders rather than increasing shareholder returns at this time [1] Group 1 - The company has stated that there is a time lag between signing orders and generating revenue, which suggests a need for patience in realizing financial results from current contracts [1] - The management team is actively working to promote the execution of existing orders, highlighting a commitment to operational efficiency and project delivery [1]

Group 1 - The core business of the company includes power station equipment and supporting infrastructure [1] - The company currently does not have any ultra-high voltage transmission and transformation projects [1]

Core Insights - The core theme of the conference was "Collaborative Win-Win: Smartly Leading the Future," focusing on enhancing chronic disease management through artificial intelligence [1][2] - The strategic partnership between Fangzhou Jianke and Suzhou Wangshan Wangshui Biopharmaceutical Co., Ltd. aims to explore innovative approaches in the health industry empowered by AI [1][6] Industry Trends - The National Health Commission issued guidelines promoting the application of AI in healthcare, outlining core goals and pathways for the next five years [2] - The aging population and the increasing prevalence of chronic diseases in younger demographics highlight the critical role of AI technology in healthcare [2] Company Developments - Fangzhou Jianke's CEO, Dr. Xie Fangmin, emphasized the importance of addressing real problems and driving genuine change in chronic disease management through AI [2][4] - The user engagement with the "AI Health Steward" platform has significantly increased, with user numbers in October being 2.4 times that of September and GMV rising by 50% [4] Strategic Collaborations - The partnership with Wangshan Wangshui is designed to integrate technological empowerment with product pipeline advantages, aiming for a comprehensive upgrade from drug supply to health services [6][8] - Both companies plan to create replicable and scalable AI-driven solutions for chronic disease management, enhancing the quality of development in the health industry [5][6]

Core Insights - The core theme of the conference was "Collaborative Win-Win: Smartly Leading the Future," focusing on enhancing chronic disease management through artificial intelligence [1][2] - A strategic partnership was formed between Fangzhou Jianke and Suzhou Wangshan Wangshui Biopharmaceutical Co., Ltd., aimed at integrating core industry resources with digital technology capabilities [1][5] Industry Trends - The Chinese government has emphasized the importance of "AI+" in various sectors, particularly in healthcare, as outlined in the recent policy documents [2] - The aging population and the increasing prevalence of chronic diseases in China present significant opportunities for AI applications in healthcare [2] Company Developments - Fangzhou Jianke's CEO, Xie Fangmin, highlighted the company's commitment to solving real problems in chronic disease management through AI technology [2][4] - The company reported a 2.4 times increase in users experiencing AI features in October compared to September, with a 50% increase in Gross Merchandise Volume (GMV) [4] Strategic Collaboration - The partnership between Fangzhou Jianke and Wangshan Wangshui aims to break down industry barriers and enhance the entire health service chain from drug supply to health services [5][6] - Both companies plan to leverage their respective strengths to create a customer-centric health service system, providing comprehensive health management solutions [5][6] Future Outlook - The collaboration is expected to facilitate a more efficient connection between biopharmaceutical research and health services, ensuring that research outcomes meet user needs [6] - Fangzhou Jianke aims to continue its focus on chronic disease management and enhance its technological foundation to drive digital upgrades in health services [6]

Core Insights - The core theme of the conference was "Collaborative Win-Win: Smartly Leading the Future," focusing on enhancing chronic disease management through artificial intelligence [1][2] Group 1: Strategic Partnerships - Ark Health and Suzhou Wangshan Wangshui Biopharmaceutical Co., Ltd. announced a strategic cooperation aimed at integrating core industry resources with digital technology capabilities [1][5] - The partnership is designed to break down industry barriers and achieve a full-chain upgrade from drug supply to health services [5][6] Group 2: AI and Chronic Disease Management - The Chinese government has emphasized the importance of "AI + healthcare," providing a clear direction for the industry's development over the next five years [2][4] - Ark Health's CEO highlighted the critical role of AI in addressing the challenges posed by an aging population and the increasing prevalence of chronic diseases [2][4] Group 3: Technological Advancements - The application of AI technology has led to significant user engagement, with a 2.4 times increase in users experiencing AI features in October compared to September, and a 50% increase in GMV [4] - The company aims to create replicable and scalable AI-driven solutions for chronic disease management, enhancing the quality of health services [4][6] Group 4: Future Outlook - The collaboration is expected to enhance the alignment between biopharmaceutical research and health service delivery, ensuring that research outcomes meet user needs more effectively [6] - Ark Health plans to continue deepening its focus on chronic disease management and strengthening its technological foundation to drive the digital transformation of health services [6]

Core Insights - The article discusses the successful convening of the Ark Health (方舟健客) Double 12 Core Partner Summit, focusing on the theme "Collaborative Win-Win, Intelligent Future," which gathered key players in the internet healthcare industry to explore the enhancement of chronic disease management through artificial intelligence [1][2] - A strategic partnership was announced between Ark Health and Suzhou Wangshan Wangshui Biopharmaceutical Co., Ltd. (旺山旺水), aimed at integrating core industry resources with digital technology capabilities to drive innovation in the health industry [1][6] Industry Trends - The Chinese government has emphasized the importance of "AI+" initiatives across various sectors, including healthcare, as part of its strategic direction for the next five years [1][2] - The aging population and the increasing prevalence of chronic diseases among younger individuals highlight the critical role AI technology can play in healthcare [2] Company Developments - Ark Health's CEO, Dr. Xie Fangmin, highlighted the company's commitment to addressing real problems and delivering tangible changes in chronic disease management through AI applications [2][5] - The company reported a significant increase in user engagement with its AI features, with a 2.4 times increase in users experiencing AI functionalities and a 50% rise in Gross Merchandise Volume (GMV) in October compared to September [4] Strategic Collaboration - The partnership between Ark Health and Wangshan Wangshui is designed to break down industry barriers and integrate technological empowerment with product pipeline advantages, facilitating a comprehensive upgrade from drug supply to health services [5][6] - Both companies aim to create a customer-centric health service system, providing tailored, efficient, and professional health management solutions throughout the entire lifecycle [6][8] Future Outlook - The collaboration is expected to enhance the connection between biopharmaceutical research and health services, ensuring that research outcomes align more closely with user needs [8] - Ark Health plans to continue its focus on chronic disease management, strengthening its technological foundation and enhancing application scenarios to promote digital transformation in health services [9]